Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Nuwellis, Inc. is a U.S.-based medical technology company focused on therapies for patients with fluid overload, particularly those suffering from heart failure and related conditions. The company operates within the medical device and cardiovascular care industries, with an emphasis on hospital-based acute and critical care settings. Its core business centers on fluid management solutions designed to precisely remove excess fluid in patients who are unresponsive to diuretic therapy.
The company’s primary revenue driver is its proprietary Aquadex FlexFlow System, a clinically differentiated ultrafiltration platform used to treat fluid overload in adult and pediatric patients. Nuwellis serves hospitals, cardiac care units, and specialty clinicians, positioning itself as a niche provider addressing an unmet clinical need where traditional pharmacologic therapies may be insufficient. The company traces its origins to 1999 as CHF Solutions, Inc. and rebranded to Nuwellis, Inc. in 2022 to reflect a broader focus on fluid management beyond congestive heart failure.
Business Operations
Nuwellis operates as a single-segment medical device company, generating revenue primarily through sales of its Aquadex FlexFlow System consoles and associated disposable components. The recurring-use disposables represent an important ongoing revenue stream, complementing capital equipment placements. The company’s technology enables controlled, low-volume fluid removal, which it markets as a safer and more precise alternative to traditional dialysis-based approaches for certain patient populations.
Operations are primarily based in the United States, with manufacturing, clinical support, and commercial activities focused on domestic hospital systems. Internationally, Nuwellis has limited exposure, relying mainly on distributor relationships in select markets. The company does not report material joint ventures, and its operations are streamlined around product development, regulatory compliance, and commercialization of its core ultrafiltration technology.
Strategic Position & Investments
Strategically, Nuwellis is focused on expanding adoption of ultrafiltration therapy through targeted clinical education, expanded indications, and deeper penetration into existing hospital customers. Growth initiatives emphasize pediatric applications, earlier intervention in heart failure treatment pathways, and generating clinical evidence to support broader physician acceptance and reimbursement stability.
The company’s investments are largely directed toward research and development, post-market clinical studies, and commercial infrastructure rather than acquisitions. Nuwellis has not disclosed any material acquisitions or a diversified subsidiary portfolio, reflecting its status as a focused, single-product-line medical device company. Its strategic positioning is centered on specialization and clinical differentiation rather than scale-based competition with larger dialysis or medtech firms.
Geographic Footprint
Nuwellis is headquartered in Minneapolis, Minnesota, and the majority of its operational footprint is concentrated in the United States. Its primary customer base consists of U.S. hospitals and healthcare systems, which account for the substantial majority of reported revenue.
Outside the U.S., the company maintains a limited international presence through distributors in parts of Europe and Asia-Pacific, where the Aquadex FlexFlow System has obtained regulatory clearances such as CE Mark approval. International operations currently represent a minor portion of overall activity, and the company’s strategic focus remains predominantly domestic.
Leadership & Governance
Nuwellis is led by an executive team with experience in medical devices, commercialization, and financial management. Leadership emphasizes disciplined capital allocation, clinical evidence generation, and focused execution within a narrowly defined therapeutic niche.
Key executives include:
- John Erb – President and Chief Executive Officer
- Kristin L. Dull – Chief Financial Officer
Data inconclusive based on available public sources regarding additional executive roles beyond those listed, as disclosures vary across filings and investor materials and do not consistently identify a broader executive roster.